Cargando…
Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial
BACKGROUND: Breath analysis is a burgeoning field, with interest in volatile organic compounds (VOCs) as a noninvasive diagnostic tool or an outcome measure, but no randomised controlled trials (RCTs) have yet evaluated this technology in a clinical trial longitudinally. In a pilot RCT, our explorat...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488227/ https://www.ncbi.nlm.nih.gov/pubmed/34616836 http://dx.doi.org/10.1183/23120541.00253-2021 |
_version_ | 1784578116578967552 |
---|---|
author | Mohan, Divya Keir, Holly R. Richardson, Hollian Mayhew, David Boyer, Joseph van der Schee, Marc P. Allsworth, Max D. Miller, Bruce E. Tal-Singer, Ruth Chalmers, James D. |
author_facet | Mohan, Divya Keir, Holly R. Richardson, Hollian Mayhew, David Boyer, Joseph van der Schee, Marc P. Allsworth, Max D. Miller, Bruce E. Tal-Singer, Ruth Chalmers, James D. |
author_sort | Mohan, Divya |
collection | PubMed |
description | BACKGROUND: Breath analysis is a burgeoning field, with interest in volatile organic compounds (VOCs) as a noninvasive diagnostic tool or an outcome measure, but no randomised controlled trials (RCTs) have yet evaluated this technology in a clinical trial longitudinally. In a pilot RCT, our exploratory objectives were feasibility of measuring VOCs via multiple techniques, assessing relationships between VOCs and Haemophilus colonisation and whether CXCR2 antagonism with danirixin altered lung microbiome composition in individuals with COPD. METHOD: 43 participants had VOCs and sputum biomarkers evaluated. VOCs and induced sputum were collected after 6 h of fasting at screening and at days 1, 7 and 14. VOCs were analysed via gas chromatography mass spectrometry (GC-MS), field asymmetric ion mobility spectrometry (FAIMS) and eNose. The primary outcome for these analyses was the relationship between VOCs and Haemophilus abundance determined by 16S rRNA sequencing. RESULTS: A joint-effects model demonstrated a modest relationship between four exhaled VOCs and Haemophilus relative abundance (R(2)=0.55) measured only by GC-MS, but not as measured using gas chromtaography FAIMS or eNose. There was considerable variability in absolute quantities of individual VOCs longitudinally. CONCLUSIONS: VOC measurement in clinical trials to identify subsets of COPD is feasible, but assessment of new VOC technologies must include concurrent GC-MS validation. Further work to standardise collection of VOCs and measuring a background or “housekeeper” VOC is required to understand and normalise individual VOC quantities. |
format | Online Article Text |
id | pubmed-8488227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-84882272021-10-05 Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial Mohan, Divya Keir, Holly R. Richardson, Hollian Mayhew, David Boyer, Joseph van der Schee, Marc P. Allsworth, Max D. Miller, Bruce E. Tal-Singer, Ruth Chalmers, James D. ERJ Open Res Original Research Articles BACKGROUND: Breath analysis is a burgeoning field, with interest in volatile organic compounds (VOCs) as a noninvasive diagnostic tool or an outcome measure, but no randomised controlled trials (RCTs) have yet evaluated this technology in a clinical trial longitudinally. In a pilot RCT, our exploratory objectives were feasibility of measuring VOCs via multiple techniques, assessing relationships between VOCs and Haemophilus colonisation and whether CXCR2 antagonism with danirixin altered lung microbiome composition in individuals with COPD. METHOD: 43 participants had VOCs and sputum biomarkers evaluated. VOCs and induced sputum were collected after 6 h of fasting at screening and at days 1, 7 and 14. VOCs were analysed via gas chromatography mass spectrometry (GC-MS), field asymmetric ion mobility spectrometry (FAIMS) and eNose. The primary outcome for these analyses was the relationship between VOCs and Haemophilus abundance determined by 16S rRNA sequencing. RESULTS: A joint-effects model demonstrated a modest relationship between four exhaled VOCs and Haemophilus relative abundance (R(2)=0.55) measured only by GC-MS, but not as measured using gas chromtaography FAIMS or eNose. There was considerable variability in absolute quantities of individual VOCs longitudinally. CONCLUSIONS: VOC measurement in clinical trials to identify subsets of COPD is feasible, but assessment of new VOC technologies must include concurrent GC-MS validation. Further work to standardise collection of VOCs and measuring a background or “housekeeper” VOC is required to understand and normalise individual VOC quantities. European Respiratory Society 2021-10-04 /pmc/articles/PMC8488227/ /pubmed/34616836 http://dx.doi.org/10.1183/23120541.00253-2021 Text en Copyright ©The authors 2021 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
spellingShingle | Original Research Articles Mohan, Divya Keir, Holly R. Richardson, Hollian Mayhew, David Boyer, Joseph van der Schee, Marc P. Allsworth, Max D. Miller, Bruce E. Tal-Singer, Ruth Chalmers, James D. Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial |
title | Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial |
title_full | Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial |
title_fullStr | Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial |
title_full_unstemmed | Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial |
title_short | Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial |
title_sort | exhaled volatile organic compounds and lung microbiome in copd: a pilot randomised controlled trial |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488227/ https://www.ncbi.nlm.nih.gov/pubmed/34616836 http://dx.doi.org/10.1183/23120541.00253-2021 |
work_keys_str_mv | AT mohandivya exhaledvolatileorganiccompoundsandlungmicrobiomeincopdapilotrandomisedcontrolledtrial AT keirhollyr exhaledvolatileorganiccompoundsandlungmicrobiomeincopdapilotrandomisedcontrolledtrial AT richardsonhollian exhaledvolatileorganiccompoundsandlungmicrobiomeincopdapilotrandomisedcontrolledtrial AT mayhewdavid exhaledvolatileorganiccompoundsandlungmicrobiomeincopdapilotrandomisedcontrolledtrial AT boyerjoseph exhaledvolatileorganiccompoundsandlungmicrobiomeincopdapilotrandomisedcontrolledtrial AT vanderscheemarcp exhaledvolatileorganiccompoundsandlungmicrobiomeincopdapilotrandomisedcontrolledtrial AT allsworthmaxd exhaledvolatileorganiccompoundsandlungmicrobiomeincopdapilotrandomisedcontrolledtrial AT millerbrucee exhaledvolatileorganiccompoundsandlungmicrobiomeincopdapilotrandomisedcontrolledtrial AT talsingerruth exhaledvolatileorganiccompoundsandlungmicrobiomeincopdapilotrandomisedcontrolledtrial AT chalmersjamesd exhaledvolatileorganiccompoundsandlungmicrobiomeincopdapilotrandomisedcontrolledtrial |